World Journal of Gastrointestinal Oncology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

1292

Figures (1-3)

267

Tables (1-4)

212

Sum=1833

Publishing Process of This Article

Item

Count

Browse

Download

309

Sum=379

Jul 15, 2024 (publication date) through May 29, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Guo Y, Li RC, Xia WL, Yang X, Zhu WB, Li FT, Hu HT, Li HL. Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(7): 3256-3269 [PMID: 39072154 DOI: 10.4251/wjgo.v16.i7.3256]
URL:	https://www.wjgnet.com/1948-5204/full/v16/i7/3256.htm

Number	Citing Articles
1	Haoying Yang, Bolei Dai, Liangjie Chen, Yingping Li, Xiaorui Jin, Chengchang Gao, Linfen Han, Xueli Bian. Iberverin Downregulates GPX4 and SLC7A11 to Induce Ferroptotic Cell Death in Hepatocellular Carcinoma Cells. Biomolecules 2024; 14(11): 1407 doi: 10.3390/biom14111407
2	Yanjun Shen, Yawen Xu, Ying Teng, Xiaoyan Ding, Jinglong Chen. First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1533471